{"title":"<i>Mycobacterium smegmatis</i> MraZ Regulates Multiple Genes within and Outside of the <i>dcw</i> Operon during Hypoxia.","authors":"Ismail Mohamed Suleiman, Huang Yu, Junqi Xu, Junfeng Zhen, Hongxiang Xu, Abulimiti Abudukadier, Amina Rafique Hafiza, Jianping Xie","doi":"10.1021/acsinfecdis.4c00665","DOIUrl":null,"url":null,"abstract":"<p><p><i>Mycobacterium tuberculosis</i> is the most ancient human tuberculosis pathogen and has been the leading cause of death from bacterial infectious diseases throughout human history. According to the World Health Organization Global Tuberculosis Report, in 2022, 7.5 million new tuberculosis cases were identified, marking the highest number of cases since the World Health Organization initiated its worldwide tuberculosis surveillance program in 1995. The 2019 peak was 7.1 million cases, with 5.8 million cases in 2020 and 6.4 million in 2021. The increase in 2022, which may be attributed to the COVID-19 pandemic complicating tuberculosis case tracing, has raised concerns. To better understand the regulation spectrum of <i>Mycobacterium smegmatis</i> <i>mraZ</i> under hypoxia, we performed a transcriptome analysis of <i>M. smegmatis</i> mutant and wild-type strains using Illumina Agilent 5300 sequencing. The study identified 6898 differentially expressed genes, which were annotated with NCBI nonredundant protein sequences, a manually annotated and reviewed protein sequence database, Pfam, Clusters of Orthologous Groups of Proteins, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes. Several mycobacteria transcriptional regulators, virulence genes, membrane transporters, and cell wall biosynthesis genes were annotated. These data serve as a valuable resource for future investigations and may offer insight into the development of drugs to combat <i>M. tuberculosis</i> infection.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.4c00665","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Mycobacterium tuberculosis is the most ancient human tuberculosis pathogen and has been the leading cause of death from bacterial infectious diseases throughout human history. According to the World Health Organization Global Tuberculosis Report, in 2022, 7.5 million new tuberculosis cases were identified, marking the highest number of cases since the World Health Organization initiated its worldwide tuberculosis surveillance program in 1995. The 2019 peak was 7.1 million cases, with 5.8 million cases in 2020 and 6.4 million in 2021. The increase in 2022, which may be attributed to the COVID-19 pandemic complicating tuberculosis case tracing, has raised concerns. To better understand the regulation spectrum of Mycobacterium smegmatismraZ under hypoxia, we performed a transcriptome analysis of M. smegmatis mutant and wild-type strains using Illumina Agilent 5300 sequencing. The study identified 6898 differentially expressed genes, which were annotated with NCBI nonredundant protein sequences, a manually annotated and reviewed protein sequence database, Pfam, Clusters of Orthologous Groups of Proteins, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes. Several mycobacteria transcriptional regulators, virulence genes, membrane transporters, and cell wall biosynthesis genes were annotated. These data serve as a valuable resource for future investigations and may offer insight into the development of drugs to combat M. tuberculosis infection.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.